Home » Graft-Versus-Host Disease: Failures and Future Opportunities
Graft-Versus-Host Disease: Failures and Future Opportunities
In September 2009, Osiris Therapeutics, Inc. reported preliminary results
from two Phase III trials evaluating its Prochymal product candidate for the treatment of acute graft-versus-host disease.
Seeking Alpha
Seeking Alpha
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May